Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.

ABSTRACT: Coxsackievirus A16 (CVA16) is one of the major pathogens responsible for human hand, foot, and mouth disease (HFMD), which has threatened the health of young children, particularly in Asia-Pacific nations. Vaccination is an effective strategy for protecting children from CVA16 infection. However, there is currently no licensed CVA16 vaccine for use in humans. In this study, we isolated a high-growth CVA16 virus strain in MRC-5 cells and developed an MRC-5-adapted vaccine candidate strain termed CVA16-393 via two rounds of plaque purification. The CVA16-393 strain was grouped into the B1b subgenotype and grew to a titre of over 10⁷ TCID₅₀/ml in MRC-5 cells. The VP1 gene region of this strain, which contains the major neutralizing epitopes, displayed high stability duri

SUBMITTER: Sun YS 

PROVIDER: S-EPMC9377242 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature